2022 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF):
| Silent period | 11 January 2022 |
| Annual report 2021 | 8 February 2022 |
| Annual General Meeting to be held at ALK Bøge Allé 1 2970 Hørsholm, Denmark Written requests to have specific business |
16 March 2022 4.00 p.m. |
| Silent period | 14 April 2022 |
| Three-month interim report (Q1) 2022 | 12 May 2022 |
| Silent period | 14 July 2022 |
| Six-month interim report (Q2) 2022 | 11 August 2022 |
| Silent period | 13 October 2022 |
| Nine-month interim report (Q3) 2022 | 10 November 2022 |
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
NEW YORK, Feb. 2, 2026 /PRNewswire/ -- The Global IoT in Healthcare Market is entering…
MURFREESBORO, TN / ACCESS Newswire / February 2, 2026 / National Health Investors, Inc. (NYSE:NHI)…
Access to an audience of over 19 million individuals monthly will expand national exposure, and…
NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…
AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…
Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…